questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 of April 2025 to Question 46588 on Abiraterone, what discussions she has had with NICE on its engagement with health authorities on the (a) appraisal and (b) use of abi
answerText: The Department has had no such discussions. Abiraterone does not have a marketing authorisation for use in the treatment of high-risk, non-metastatic prostate cancer and has not been evaluated for that indication by the National Institute for Health and C...
heading: Abiraterone